Press Releases

Showing Press Releases: 1–10 of 11

CoLucid Pharmaceuticals to Present at the Biotech Showcase during J.P. Morgan Healthcare Conference
CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
CoLucid Founder Passes Away
CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Phase 2 Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound

Migraine Attack

May start with a warning phase involving tiredness and abnormal sensitivity to noise, lights or smells

May be preceded by “Aura” - flashing lights, small areas of temporary visual loss and tingling or numbness on one side of the face Headache usually one-sided, throbbing, and moderate or severe in intensity, worsening by movement

Accompanied by nausea and vomiting and light and sound sensitivity

Lasts from 4 to 72 hours and be followed by tiredness, mood changes and difficulty concentrating

Migraineurs suffer on average three migraines per month

More On Colucid

Migraine Attack